[Trifluorothymidin-prophylaxis of dendritic keratitis in steroid-treated herpetic keratouveitis (author's transl)].
In a randomized double-blind study trifluorothymidine was tested for its ability to prevent dendritic keratitis at a dose of 5 drops daily in patients with steroid-treated herpetic keratouveitis. The corneal epithelium of all 56 patients in the study was free of viral foci prior to initiation of therapy. In the placebo- "protected" group, 6 of 28 patients developed virologically confirmed dendritic keratitis while they were under steroids, whereas all 28 trifluorothymidine-protected patients showed uneventful courses of their steroid regimes. No clinically relevant side-effects of trifluorothymidine prophylaxis were observed in this study.
D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000008:administration & dosage*; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D007635:Keratitis, Dendritic / Q000517:prevention & control*; D009883:Ophthalmic Solutions; D013936:Thymidine / Q000031:analogs & derivatives*; D014271:Trifluridine / Q000627:therapeutic use*; D014605:Uveitis / Q000188:drug therapy*
D009883:Ophthalmic Solutions; D003907:Dexamethasone; D014271:Trifluridine; D013936:Thymidine
Trifluorthymidinprophylaxe bei der Steroidtherapie herpetischer Keratouveitiden.